Human Organs Inquiry - Post Mortem Examinations (PDF 441 KB)

Good Practice in Consent and Care of the Bereaved

Post Mortem Inquiry - Progress Report To The Minister for Health and Children

The Inquiry is of the view that the Terms of Reference are wide ranging and comprehensive. The issue of organ retention is not one which may be examined properly in isolation and involves consideration of many issues,  most notably the legal context within which the matters arise. The issue is one which needs to be seen in its proper context so that it may be properly and fully understood. Progress Report Addendum to Progress Report

Report of the Working Group on Post Mortem Practice

The Madden Report into Post Mortem Practice and Procedure (2005)1 stated that consideration should be given to the implementation of the recommendations made in the Report to other post mortems2, namely those carried out on babies who died before or during birth, minors and adults. It was acknowledged that while many of the recommendations in the Report may apply generically to all categories of post-mortem examinations, these post mortems also raise distinct legal and ethical issues that were not within the Terms of Reference of the Madden Report. The Report advised that a Working Group be established to ensure that appropriate adaptation in relation to those issues takes place. The terms of reference were: Read the report (PDF, 117kb)

Report of Dr Deirdre Madden on Post Mortem Practice and Procedures

This Report aims to set out the general facts in relation to paediatric post-mortem practice in Ireland from 1970 to 2000, the way in which information was communicated to parents of deceased children in relation to post-mortemexaminations, and how these practices might be improved upon for the future Read the Report  

Advice Letter from Dr Carson DCMO (PDF 141 KB)

Letter from Dr Carson advising of new arrangements re post mortem documentation

Chronology of Events in relation to Organ Retention Inquiry

  Mid 1999 Investigation into cardiac surgery practice on children at Bristol Royal Infirmary. Dec 1999 Inquiry into organ retention in Alder Hey Children’s Hospital in Liverpool. May 1999: Contact from Our Lady’s Hosptial Crumlin re pathology and post mortem practice Dec 1999 PFJ meetings with Minister Apr 2000: Government Decision setting up Inquiry. Apr 2000: Ms Anne Dunne appointed Chairman. Feb 2001: Public Notice published, setting out terms of reference of Inquiry and inviting submissions. Mar 2001: Terms of Reference and Interpretation Published. Contact invited. “Six months N/A. Now 18 months” Jun 2001: Department commenced Discovery. Aug 2001: Memorandum on procedures received in Department. Sept 2002: 18 months time-frame had expired. Minister requested a meeting with Ms Anne Dunne. This happened in early September – Minister requested a progress report. 2 Oct 02 Ms Dunne’s progress report received by Minister – although substantial progress no definitive timeframe for completion of her work – a lot more work outstanding. Co-operation forthcoming from all parties 16 Oct 2002: Minister’s meeting with Parents for Justice – he assured them of his commitment to resolve any difficulties, but they decided to withdraw from the Inquiry process 2004: Minister calls on PFJ to co-operate. Chairman informs Minister that she has sufficient involvement of parents to conclude her report. Minister expects paediatric report by the end of the year

Alzheimer's Disease Biomarkers, 2009

This report gives a comprehensive and up-to-date review of Alzheimer's disease biomarkers. Recent years have seen significant advances in this field. Whilst considerable effort has focused on A�_ and tau related markers, a substantial number of other molecules have been identified, that may offer new opportunities.This Report : Identifies 60 candidate Alzheimer's (AD) biomarkers and their associated studies. Of these, 49 are single species or single parameters, 7 are combinations or panels and 4 involve the measurement of two species or parameters or their ratios. These include proteins (n=34), genes (n=11), image-based parameters (n=7), small molecules (n=3), proteins + genes (n=2) and others (n=3). Of these, 30 (50%) relate to species identified in CSF and 19 (32%) were found in the blood. These candidate may be classified on the basis of their diagnostic utility, namely those which i) may allow AD to be detected when the disease has developed (48 of 75†= 64%), ii) may allow early detection of AD (18 of 75† = 24%) and iii) may allow AD to be predicted before the disease has begun to develop (9 of 75†= 12%). † Note: Of these, 11 were linked to two or more of these capabilities (e.g. allowed both early-stage detection as well as diagnosis after the disease has developed).Biomarkers: AD biomarkers identified in this report show significant diversity, however of the 60 described, 18 (30%) are associated with amyloid beta (A�_) and 9 (15%) relate to Tau. The remainder of the biomarkers (just over half) fall into a number of different groups. Of these, some are associated with other hypotheses on the pathogenesis of AD however the vast majority are individually unique and not obviously linked with other markers. Analysis and discussion presented in this report includes summaries of the studies and clinical trials that have lead to the identification of these markers. Where it has been calculated, diagnostic sensitivity, specificity and the capacity of these markers to differentiate patients with suspected AD from healthy controls and individuals believed to be suffering from other neurodegenerative conditions, have been indicated. These findings are discussed in relation to existing hypotheses on the pathogenesis of the AD and the current drug development pipeline. Many uncertainties remain in relation to the pathogenesis of AD, in diagnosing and treating the disease and many of the studies carried out to identify disease markers are at an early stage and will require confirmation through larger and longer investigations. Nevertheless, significant advances in the identification of AD biomarkers have now been made. Moreover, whilst much of the research on AD biomarkers has focused on amyloid and tau related species, it is evident that a substantial number of other species may provide important opportunities.Purpose of Report: To provide a comprehensive review of important and recently discovered candidate biomarkers of AD, in particular those with potential to reliably detect the disease or with utility in clinical development, drug repurposing, in studies of the pathogenesis and in monitoring drug response and the course of the disease. Other key goals were to identify markers that support current pipeline developments, indicate new potential drug targets or which advance understanding of the pathogenesis of this disease.Drug Repurposing: Studies of the pathogenesis of AD have identified aberrant changes in a number of other disease areas including inflammation, diabetes, oxidative stress, lipid metabolism and others. These findings have prompted studies to evaluate some existing approved drugs to treat AD. This report identifies studies of 9 established drug classes currently being investigated for potential repurposing.Alzheimer’s Disease: In 2005, the global prevalence of dementia was estimated at 25 million, with more than 4 million new cases occurring each year. It is also calculated that the number of people affected will double every 20 years, to 80 million by 2040, if a cure is not found. More than 50% of dementia cases are due to AD. Today, approximately 5 million individuals in the US suffer from AD, representing one in eight people over the age of 65. Direct and indirect costs of AD and other forms of dementia in the US are around $150 billion annually. Worldwide, costs for dementia care are estimated at $315 billion annually. Despite significant research into this debilitating and ultimately fatal disease, advances in the development of diagnostic tests for AD and moreover, effective treatments, remain elusive.Background: Alzheimer's disease is the most common cause of dementia, yet its clinical diagnosis remains uncertain until an eventual post-mortem histopathology examination is carried out. Currently, therapy for patients with Alzheimer disease only treats the symptoms; however, it is anticipated that new disease-modifying drugs will soon become available. The urgency for new and effective treatments for AD is matched by the need for new tests to detect and diagnose the condition. Uncertainties in the diagnosis of AD mean that the disease is often undiagnosed and under treated. Moreover, it is clear that clinical confirmation of AD, using cognitive tests, can only be made after substantial neuronal cell loss has occurred; a process that may have taken place over many years. Poor response to current therapies may therefore, in part, reflect the fact that such treatments are generally commenced only after neuronal damage has occurred. The absence of tests to detect or diagnose presymptomatic AD also means that there is no standard that can be applied to validate experimental findings (e.g. in drug discovery) without performing lengthy studies, and eventual confirmation by autopsy.These limitations are focusing considerable effort on the identification of biomarkers that advance understanding of the pathogenesis of AD and how the disease can be diagnosed in its early stages and treated. It is hoped that developments in these areas will help physicians to detect AD and guide therapy before the first signs of neuronal damage appears. The last 5-10 years have seen substantial research into the pathogenesis of AD and this has lead to the identification of a substantial number of AD biomarkers, which offer important insights into this disease. This report brings together the latest advances in the identification of AD biomarkers and analyses the opportunities they offer in drug R&D and diagnostics.��

IPH response to the Strategic Review of Health Inequalities in England post 2010

IPH contributed to the Strategic Review of Health Inequalities in England being carried out by Professor Sir Michael Marmot, Chair of the Commission on the Social Determinants of Health.  IPH acknowledges the immense work done by the Review team and welcomes the opportunity to inform its work. We see the review as a vital opportunity to provide a “catalyst for concerted action” not only in England but in its near neighbours in Northern Ireland and Ireland. Health inequalities are rife across the UK and Ireland despite a range of developments in policy and practice designed to create more equal opportunities for health. We commend the approach taken in the Review, which applies scientific rigour and the combined expertise of a number of defined task groups to seek solutions to the vexing challenge of health inequality.

Inspection of Social Care Support Services for Carers of Older People (PDF 1776 KB)

Social Services Inspection Final Report for Craigavon & Banbridge - fieldwork inspection 14-25 Nov 2005

Inspection of Social Care Support Services for Carers of Older People (PDF 494 KB)

Down Lisburn Health And Social Services Trust Eastern Health And Social Services Board Fieldwork Inspection: 31st May 2005 - 10th June 2005 (Final Report April 2006)

Issues Paper: Consultation on The Review of the Post Qualifying Framework (PDF 97 KB)

Issues Paper: Consultation on The Review of the Post Qualifying Framework

The Fire Authority for Northern Ireland Inspection Report (PDF 67 KB)

Northern Ireland Fire Brigade - 10th and 11th March 2005

Inspection of Social Work in Mental Health Services

Inspection of Social Work in Mental Health Services